Intravenous Dofetilide for Arrhythmic Storm Termination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for administering dofetilide to patients in arrhythmic storm following implantation of a cardiac defibrillator are impractical due to the 3-day oral loading regimen, which is inadequate for immediate treatment and poses risks of excessive QTc prolongation.
Innovation Solution
Intravenous loading and maintenance infusion of dofetilide followed by a switch to oral dosing, with careful monitoring of QTc intervals to ensure safe and effective serum concentration, allowing for rapid termination of arrhythmic storm and prevention of life-threatening arrhythmias.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral dofetilide is used for chronic therapy, then steady state concentration is achieved, but it takes at least 3 days for loading which is unsatisfactory for immediate treatment
Solution Approach 1:
The patent changes the administration parameter from oral to intravenous, which fundamentally alters the pharmacokinetic profile. IV administration provides immediate bioavailability and allows for rapid achievement of steady state concentration within hours rather than days, while maintaining the same therapeutic effect.
Solution Approach 2:
The patent implements a preliminary intravenous loading dose followed by a maintenance infusion before transitioning to oral dosing. This preliminary action ensures that therapeutic concentration is achieved immediately and maintained reliably during the critical initial period, overcoming the 3-day delay of oral loading.
2Speed
If intravenous dofetilide is administered rapidly, then arrhythmic storm is terminated quickly, but excessive QTc prolongation may occur
Solution Approach 1:
The patent incorporates continuous ECG monitoring and QTc interval assessment as feedback mechanisms throughout the intravenous loading and maintenance phases. Based on this feedback, the dosing is adjusted in real-time to achieve rapid termination of arrhythmic storm while preventing excessive QTc prolongation and Torsades de Pointe.
Solution Approach 2:
The patent employs a dynamic dosing approach where the intravenous loading dose is followed by a maintenance infusion that can be adjusted based on patient response and QTc changes. This dynamic adjustment allows for rapid achievement of therapeutic concentration while adapting to individual patient tolerability to avoid harmful QTc prolongation.
3Loss of time
If intravenous dofetilide is used instead of oral, then loading time is reduced, but monitoring complexity increases
Solution Approach 1:
The patent uses ECG monitoring as an intermediary tool to bridge the gap between rapid IV administration and safety assessment. The continuous ECG provides real-time data on QTc interval changes, enabling safe dosing decisions during the intensive IV loading phase without requiring complex monitoring systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables rapid and controlled achievement of effective dofetilide concentrations, reducing the risk of arrhythmic storm recurrence and facilitating earlier transition to oral dosing, thus improving patient safety and treatment efficacy.
Implementation Method 1
Dofetilide does this by blocking the outward potassium channel IKr (rapid potassium rectifier current)
Implementation Method 2
Its action is to prolong the action potential duration, specifically by prolonging repolarization time
Data Source
AI summary
The invention involves a novel method of terminating arrhythmic storm in patients following implementation of an implantable defibrillator by administrating loading and maintenance infusions of dofetilide intravenously followed by oral dosing.